- Home
- UCAR vs CANF Comparison
UCAR vs CANF Comparison
Compare UCAR & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UCAR | CANF |
|---|---|---|
| Founded | 2013 | 1994 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 6.7M |
| IPO Year | 2022 | 2011 |
Fundamental Metrics
Financial Performance| Metric | UCAR | CANF |
|---|---|---|
| Price | $3.28 | $1.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 5.4K | ★ 25.6K |
| Earning Date | 11-03-2026 | 09-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.04 | $0.17 |
| 52 Week High | $8.99 | $10.40 |
Technical Indicators
Market Signals| Indicator | UCAR | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 43.46 | 30.85 |
| Support Level | $1.05 | N/A |
| Resistance Level | $4.19 | $2.27 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | -0.15 | 0.01 |
| Stochastic Oscillator | 3.49 | 23.75 |
Price Performance
Historical ComparisonAbout UCAR U Power Limited
U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.